The leucine-rich repeat-containing protein 15 (LRRC15) is a cell surface protein involved in cell-cell and cell-matrix interactions, with limited expression in normal tissues.
The use of mimicking antibodies that activate death receptors (DRs) to selectively induce cell death in cancer cells has shown limited clinical success so far, primarily due to suboptimal efficacy and safety concerns, particularly hepatotoxicity. Emerging strategies to enhance efficacy include the development of bispecific antibodies that simultaneously target DRs and tumor-specific antigens.
Abnormal fusion of the FGFR2 gene, encoding the fibroblast growth factor receptor 2, occurs in several types of cancer, including in up to 15% of cases of intrahepatic cholangiocarcinoma.
Multiple myeloma (MM) is a complex disease with poor prognosis and its clinical management still remains a challenge in the field. Since both BCMA and GPRC5D are overexpressed in MM cells, a therapeutic approach targeting both would be of interest. Qilu Pharmaceutical Co. Ltd. is hence developing a dual BCMA- and GPRC5D-targeting antibody – QLS-4131 – for the treatment of MM.
HER3 overexpression in solid tumors is tied to poor prognosis, concretely in breast and non-small-cell lung cancers, where treatment resistance often occurs upon using targeted therapy, highlighting the need for novel targeted therapies against HER3. Since its expression is much higher in tumor than normal cells, HER3 is a robust candidate for antibody-drug conjugate (ADC) therapy.
Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets trophoblast cell surface antigen 2 (TROP2), which is overexpressed in most pancreatic tumors and is associated with aggressive disease and poor prognosis.
Onward Therapeutics SA’s subsidiary Emercell SAS has received investigational medicinal product dossier (IMPD) approval from the EMA to initiate a phase I trial of OT-C001, an allogeneic natural killer (NK) cell therapy, in combination with an anti-CD20 monoclonal antibody, rituximab.
Tagworks Pharmaceuticals BV has received IND clearance from the FDA for a phase I trial evaluating its antibody-drug conjugate (ADC) TGW-101 in patients with advanced solid tumors. The company has initiated the first-in-human trial.
RSS
